<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02721342</url>
  </required_header>
  <id_info>
    <org_study_id>Remission Clinic</org_study_id>
    <nct_id>NCT02721342</nct_id>
  </id_info>
  <brief_title>Remission Clinic in Proteinuric Chronic Nephropathies</brief_title>
  <official_title>Remission Clinic: Computed Registry for the Ambulatory Follow up of Patients With Proteinuric Chronic Nephropathies Treated Based on a Standard Multipharmacological Model Aimed at Normalizing Proteinuria and Stabilizing the Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mario Negri Institute for Pharmacological Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most chronic kidney diseases have a progressive evolution characterized by the gradual loss&#xD;
      of glomerular filtration rate (GFR), electrolytic imbalance, reduced erythropoietin synthesis&#xD;
      and activation of vitamin D. On many occasions, the progressive deterioration of renal&#xD;
      function occurs, even when the etiologic factors responsible for the kidney disease are&#xD;
      treated and/or eliminated as a result of an auto-sustained mechanism of inflammation and&#xD;
      fibrosis. Moreover, chronic nephropathies are often associated with high blood pressure and&#xD;
      increased urine protein excretion, being both risk factors of progression toward kidney&#xD;
      failure. Many clinical studies have shown the efficacy of antihypertensive therapies,&#xD;
      particularly the blockade of renin-angiotensin system, to lower the abnormal urinary protein&#xD;
      excretion. Moreover, control of blood pressure and proteinuria slow the rate of renal&#xD;
      function decline and in some cases even lead to recovery of kidney function avoiding the need&#xD;
      for renal replacement therapies. The set of measures to achieve these results encompasses the&#xD;
      term of &quot;renoprotective therapy&quot;. However these achievements have been obtained in the&#xD;
      setting of clinical trials, and need confirmation in the daily clinical practice.&#xD;
&#xD;
      To this purpose a standardized multidrug intervention model that aims at normalizing the&#xD;
      excretion of urinary proteins and stabilizing the renal function has been developed for the&#xD;
      outpatient-clinic and named &quot;Remission Clinic&quot;.&#xD;
&#xD;
      The applicability of this protocol is aimed for all nephrology and diabetology centers.&#xD;
      Through the use of a dedicated database computer network, it will be possible to share&#xD;
      clinical, laboratory and treatment data, recorded for each patient enrolled in the Remission&#xD;
      Clinic program. With this system, it will be possible to verify if the multidrug approach of&#xD;
      the Remission Clinic will allow to improve the clinical course of chronic proteinuric&#xD;
      nephropathy. All participants (centers) may access to the Remission Clinic website developed,&#xD;
      updated and maintained by the Department of Bioengineering of the Mario Negri Institute,&#xD;
      Bergamo, Italy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Glomerular Filtration Rate (GFR) estimated</measure>
    <time_frame>Changes from baseline at at least every 3 to 6 months for the duration of the study, an expected average of 10 years.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hour proteinuria</measure>
    <time_frame>Changes from baseline at at least every 3 to 6 months for the duration of the study, an expected average of 10 years.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with fatal and non-fatal cardiovascular events</measure>
    <time_frame>Participants will be followed for the duration of the study, an expected average of 10years.</time_frame>
    <description>Sudden death, myocardial infarction, unstable angina, stroke, transient ischemic attack, lower limb amputation, coronary, carotid or peripheral vessel revascularization.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Ramipril, Irbesartan and Atorvastin treatment</arm_group_label>
    <description>A multidrug approach, including Angiotensin II Converting Enzyme (ACE) inhibitor, Ramipril, and Angiotensin II Receptor Blocker (ARB), Irbesartan, and Atorvastin will be done. Treatment doses of drugs will be up-titrated gradually considering the tolerability.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril, Irbesartan and Atorvastin</intervention_name>
    <arm_group_label>Ramipril, Irbesartan and Atorvastin treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diabetic or non-diabetic chronic nephropathies, with no specific&#xD;
        contraindications for treatment with ACEi or Sartans.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Proteinuria &gt;0.5 g/24 hours or albuminuria &gt;200 g / min (or &gt;300 g/24 hours) for at&#xD;
             least 2 consecutive evaluations regardless of treatment with ACEi and/or ARBs;&#xD;
&#xD;
          -  Change in serum creatinine or creatinine clearance less than 30% in the last 3 months;&#xD;
&#xD;
          -  No corticosteroids or immunosuppressants at the time of inclusion or given to patient&#xD;
             in the last 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Idiopathic membranous nephropathy;&#xD;
&#xD;
          -  Focal segmental glomerulosclerosis;&#xD;
&#xD;
          -  Minimal change glomerulopathy;&#xD;
&#xD;
          -  Nephritic syndrome;&#xD;
&#xD;
          -  Rapidly progressive renal failure (extracapillary glomerulonephritis in active phase);&#xD;
&#xD;
          -  Any active renal disease that represents a possible indication to corticosteroids or&#xD;
             immunosuppressive therapy;&#xD;
&#xD;
          -  Nephropathies secondary to systemic disease susceptible to treatment with&#xD;
             corticosteroids or immunosuppressive agents (Systemic Lupus Erythematosus, Vasculitis,&#xD;
             Amyloidosis, etc.).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò</name>
      <address>
        <city>Ranica</city>
        <state>Bergamo</state>
        <zip>24020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Morgagni - Pierantoni - U.O. Nefrologia e Dialisi</name>
      <address>
        <city>Forlì</city>
        <state>Forli'</state>
        <zip>47011</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asl 6 Sanluri-P.O. Nostra Signora di Bonaria - U.O. Nefrologia e Dialisi</name>
      <address>
        <city>San Gavino- Monreale</city>
        <state>Medio Campidano - VS</state>
        <zip>09037</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale C.G. Mazzoni Zona 13 ASUR Marche - U.O. Nefrologia e Dialisi</name>
      <address>
        <city>Ascoli Piceno</city>
        <zip>63100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AORN Moscati - Avellino - U.O. Nefrologia e Dialisi</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Papa Giovanni XXIII - U.O. Nefrologia e Dialisi</name>
      <address>
        <city>Bergamo</city>
        <zip>20147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Papa Giovanni XXIII Bergamo - U.O. Diabetologia</name>
      <address>
        <city>Bergamo</city>
        <zip>20147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera G. Brotzu - U.O. Nefrologia e Dialisi</name>
      <address>
        <city>Cagliari</city>
        <zip>09100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Campo di Marte - USL 2 - U.O. Nefrologia</name>
      <address>
        <city>Lucca</city>
        <zip>55100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARNAS Ospedale Civico Di Cristina Benfratelli - U.O. Nefrologia e Dialisi</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Università degli Studi di Palermo - Dipartimento Malattie Cardiovascolari e Nefrourologiche - U.O. Tecniche Dialitiche</name>
      <address>
        <city>Palermo</city>
        <zip>90129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Pisana - U.O. Nefrologia e Dialisi 2</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo Fondazione Macchi - U.O. Nefrologia e Dialisi</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 14, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2016</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic proteinuric nephropathies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Irbesartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

